Previous Close | 120 |
1-Year Change | 60.75% |
6-Months Change | 17.41% |
3-Months Change | 7.46% |
Moving Avg (50d) | 114.67 |
Moving Avg (200d) | 102.57 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.09B |
Beta (3-Years) | 1.13 |
Revenue Growth (ttm) | -24.06% |
Net Profit Margin (ttm) | 10.73% |
Return On Assets (ttm) | 2.14% |
EPS (ttm) | 0.82 |
PE Ratio (ttm) | 146.34 |
Dividend Yield | % |
Asset Description: | Ligand Pharmaceuticals Incorporated |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2025-02-14 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
117.6 | 114 | 111.6 | 108 | 102 | 96 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenix Inc., the company went public in 1992. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and forming partnerships to develop... Wikipedia